Arthritis

Silo Pharma is pursuing a development plan utilizing its liposomal joint homing peptides as a potential therapy for rheumatoid arthritis (RA). In the most ...

All statements other than statements of historical fact in this announcement are forward-looking statements that involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy, and financial needs. Earlier results of the same study successfully demonstrated that the subcutaneous (SC) route of liposomal administration (small needle injection into shallow soft tissue just under the layer of skin) is well-suited for use in targeted drug delivery of anti-arthritic agents. “Since patients widely prefer SC administration over intravenous (IV) infusion for multiple reasons, we believe the superiority and practicality of our liposomal joint homing peptide bode well for broad market potential. Silo Pharma is pursuing a development plan utilizing its liposomal joint homing peptides as a potential therapy for rheumatoid arthritis (RA). (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced positive interim data from its dose optimization study of SPU-21 joint homing peptides for subcutaneous administration of anti-arthritic agents. The drug used in the study was dexamethasone (DEX), a corticosteroid used for its anti-inflammatory and immunosuppressant effects.

Silo Pharma said it is pursuing a development plan utilizing its liposomal joint homing peptides as a potential therapy for rheumatoid arthritis (RA). SILO, ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. (RTTNews) - Shares of Silo Pharma, Inc. Silo Pharma said it is pursuing a development plan utilizing its liposomal joint homing peptides as a potential therapy for rheumatoid arthritis (RA).

By Sabela Ojea Shares of Silo Pharma Inc. on Friday jumped 68% in premarket trading after the biotechnology company said that an arthritis-treatment study.

Write to Sabela Ojea at [email protected] By Sabela Ojea Shares were trading at $5.81, up from the company's latest closing price of $3.42 a share.

(Nasdaq: SILO) today announced positive interim data from its dose optimization study of SPU-21 joint homing peptides for subcutaneous administration of anti- ...

“Since patients widely prefer SC administration over intravenous (IV) infusion for multiple reasons, we believe the superiority and practicality of our liposomal joint homing peptide bode well for broad market potential. Earlier results of the same study successfully demonstrated that the subcutaneous (SC) route of liposomal administration (small needle injection into shallow soft tissue just under the layer of skin) is well-suited for use in targeted drug delivery of anti-arthritic agents. Silo Pharma is pursuing a development plan utilizing its liposomal joint homing peptides as a potential therapy for rheumatoid arthritis (RA). The drug used in the study was dexamethasone (DEX), a corticosteroid used for its anti-inflammatory and immunosuppressant effects. The effect of lipo-DEX was superior to that of DEX alone when both were administered via the SC route,” said Eric Weisblum, Chief Executive Officer of Silo Pharma. [Wall St set to end challenging year with steep drop](ETFs/Wall+St+set+to+end+challenging+year+with+steep+drop/21017826.html) [Wall Street analysts weigh on Tesla (TSLA) - one of S&P 500's biggest losers in 2022](Analyst+Comments/Wall+Street+analysts+weigh+on+Tesla+%28TSLA%29+-+one+of+S%26P+500s+biggest+losers+in+2022/21018031.html) [U.S.

Arthritis is a fact of life for a lot of people out there, and Silo Pharma (NASDAQ:SILO) may have just the thing to help. Silo recently announced the ...

Over the course of the trading day, Silo lost virtually all those gains. The last five days of trading for Silo Pharma delivered unexpected results. Yet, given that Silo also has some solid preclinical data out for its Alzheimer’s treatment, known as SPC-14, that should help Silo advance in the market instead of turning downward like we saw today.